Biotechnology firms to draw investors post-pandemic

covid-19/coronavirus/Janus-Henderson/healthcare/

8 April 2020
| By Oksana Patron |
image
image image
expand image

The healthcare sector has outperformed the broad equity market during the coronavirus crisis as investors reward companies with advanced research to address COVID-19 and could continue to invest in biotechnology firms after the pandemic ends, Janus Henderson’s portfolio manager Andy Acker said.

Although healthcare stocks tended to act more defensively during an economic contraction, in these circumstances, there was not a steady stream of surgeries or doctor’s visits that were expected to help prop up healthcare companies. On top of that social distancing and preparations for a surge of coronavirus patients sidelined many of these routine activities, he said.

However, investors continued to reward those companies which were using innovation to aggressively develop vaccines or treatments for COVID-19, while firms helping to facilitate remote medical care were also gaining favour.

“Investor focus on these trends has accelerated due to the crisis but could last long after the pandemic ends, in our view,” Acker stressed.

“Although we are sceptical of the rally in certain biotechnology companies making headlines as it relates to the virus, we believe investor focus on the sector’s advanced technology could last long after the pandemic ends.”

At the same time, investors acknowledged that tele-medicine services were taking off as both Government and insurers encouraged the technology’s use as an efficient and safe means to treat influenza and potential COVID-19 infections, easing the burden on the healthcare system.

Although the advances were encouraging, Acker warned that investors should keep perspective and stressed it was very likely that we would not have a vaccine for the general population for at least 12 to 18 months.

“We think investors should expect continued volatility in the coming months. However, we believe the rapid pullback of equity prices has created some compelling opportunities,” he said.

“Longer term, we feel that the sector’s unprecedented innovation addressing unmet medical needs will lead to attractive growth – a point we think is now being driven home by the global race for a coronavirus cure.”

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

So we are now underwriting criminal scams?...

4 months 3 weeks ago

Glad to see the back of you Steve. You made financial more expensive, not more affordable as you claim, and presided ...

5 months ago

Completely agree Peter. The definition of 'significant change is circumstances relevant to the scope of the advice' is s...

7 months ago

Commonwealth Bank has formally dropped to zero advisers following LGT Crestone’s acquisition of its advice arm – some six years on from the Hayne royal commission. ...

3 weeks 5 days ago

The FSCP has issued a written direction to an adviser who charged clients “extraordinary fees” for inappropriate and conflicted advice, as well as encouraged them to swit...

1 week 2 days ago

ASIC has cancelled the AFSL of an advice firm associated with Shield and First Guardian collapses, and permanently banned its responsible manager. ...

2 weeks 4 days ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND
Fund name
3y(%)pa
1
DomaCom DFS Mortgage
92.15 3 y p.a(%)
3